Treating LPR:
What the Evidence Actually Supports
LPR is frequently mismanaged because it is treated like GERD. Because pepsin — not acid — is the primary agent of damage, the treatment approach must be fundamentally different. This guide explains what the evidence shows, why PPIs so often fall short, and what actually works.
Simple home saliva test · No GP referral required · CE-IVD certified diagnostic
Why LPR Treatment Differs from GERD
The single most important thing to understand about LPR treatment is that it targets a different mechanism from GERD. In GERD, the primary problem is acid refluxing into the oesophagus, and acid suppression — PPIs, H2 blockers — directly addresses the cause. In LPR, the primary agent of tissue damage is pepsin, a digestive enzyme that reaches the throat and larynx during reflux events. Pepsin remains stable at neutral pH and active at pH levels up to 6.5, far above what acid-suppressing medication targets. Reducing stomach acid production does not remove pepsin from the equation.
This means that a treatment strategy designed primarily for GERD will always be an imperfect fit for LPR. It may reduce the frequency of reflux events. It may lower symptoms in patients who have both conditions. But it does not address the core mechanism of laryngeal damage — which is why so many patients with confirmed LPR continue to experience symptoms despite years of PPI therapy. The treatment approach for LPR must account for pepsin specifically: through physical barrier therapy to prevent reflux from reaching the throat, through dietary changes that avoid reactivating deposited pepsin, and through objective monitoring of whether pepsin remains present. For the full science of how pepsin causes tissue damage — including the endocytosis mechanism — see our detailed pepsin science guide.
There is a further complexity that recent evidence has highlighted. Not every patient with LPR-type symptoms has LPR alone. A 2026 case series published in the Journal of Voice by Lechien et al. (n=143, doi: 10.1016/j.jvoice.2026.01.036) found that 75% of patients with persistent LPR symptoms had at least one co-condition mimicking or aggravating their presentation — including inhaled steroid laryngitis, postnasal drip, allergies, lactose intolerance, and chronic rhinosinusitis. Treatment response rates jumped from 47.9% to 80.6% when these co-conditions were identified and managed alongside LPR.
The Lechien findings change how we should think about objective pepsin testing. A positive Peptest result confirms the reflux component is real and active — giving clinician and patient a firm foundation to treat LPR specifically, and to evaluate response against a known baseline.
A negative result in a symptomatic patient shifts the differential toward co-conditions of exactly the kind Lechien identified: inhaled steroid laryngitis, postnasal drip, lactose intolerance, rhinosinusitis. These conditions require entirely different management, and pursuing aggressive LPR treatment in their absence wastes months of a patient's life.
For patients who test positive but are not improving as expected, Peptest provides the baseline: LPR is confirmed, but co-conditions may be contributing alongside it — a very different clinical picture from LPR that isn't responding because it isn't actually LPR. Objective pepsin testing doesn't just confirm the diagnosis. It directs the treatment pathway.
The Evidence on PPIs for LPR
If you have been prescribed PPIs for throat symptoms — omeprazole, lansoprazole, pantoprazole — and found them only partially helpful or completely ineffective, you are not unusual. PPIs are the most commonly prescribed treatment for LPR, but the randomised controlled trial evidence for their use specifically in LPR is, at best, modest.
The most significant trial to date is O'Hara et al. (BMJ, 2021) — a multicentre, double-blind randomised controlled trial that found no overall benefit of PPIs for persistent throat symptoms consistent with LPR. This was not a small study or a preliminary finding: it was a rigorously designed RCT conducted across multiple sites, and its conclusion reflects what many patients already know from experience. This does not mean the clinicians who prescribed PPIs were wrong to do so — PPIs remain appropriate for managing GERD and for patients with mixed presentations. But for LPR specifically, they are insufficient as sole treatment.
The mechanistic reason is straightforward. Research by Crossfield et al. (2013) demonstrated that pepsin remains detectable in patients taking PPI therapy — meaning that even when acid output is suppressed, the enzyme responsible for laryngeal damage continues to reach the throat during reflux. PPIs reduce the acidity of the reflux; they do not prevent reflux from occurring, and they do not remove pepsin from it. For the full explanation of why pepsin causes damage independently of acid, see our pepsin science guide — PPI section.
For patients who have spent months or years on PPIs without resolution, this evidence is worth understanding clearly: your treatment response does not determine whether you have reflux. It may simply mean you have LPR rather than GERD, and the treatment approach needs to change.
What to Discuss with Your GP
Many patients with LPR feel stuck: they have been given PPIs, they haven't improved, and they don't know what to ask for next. The evidence above gives you a clinical framework — and there are specific, concrete steps worth raising with your GP.
Ask about alginate rather than more PPIs
If PPIs have not resolved your throat symptoms, the evidence supports asking about alginate therapy — specifically Gaviscon Advance — rather than continuing or escalating acid suppression. Explain that your symptoms are predominantly in your throat rather than your chest, and reference the O'Hara 2021 BMJ RCT if helpful. See the alginate section below for the clinical rationale to share.
Request ENT referral if symptoms persist
Persistent unexplained hoarseness, voice changes, or chronic throat symptoms that have not responded to initial treatment warrant ENT assessment. An ENT specialist can perform laryngoscopy to look for signs of laryngeal inflammation — erythema, oedema, posterior glottic changes — and will be familiar with LPR as a diagnosis in a way that many GPs are not.
Bring your Peptest result as clinical evidence
Every Peptest result comes with a GP letter that translates the finding into clinical language — whether the result is positive (pepsin detected, reflux confirmed) or negative (pepsin not detected, which redirects the investigation). A positive result gives your GP objective biomarker evidence to act on. A negative result in a patient with ongoing symptoms is itself clinically important — it changes the differential diagnosis and may prompt investigation of co-conditions. Either way, it shifts the conversation from symptom reporting to objective data.
Raise co-conditions if improvement is incomplete
If you are on treatment but not improving as expected, it is worth asking your GP to consider whether a co-condition may be contributing. The Lechien 2026 Journal of Voice study found that 75% of persistent LPR patients had at least one co-condition — including inhaled steroid laryngitis, postnasal drip, and allergies. A Peptest result confirms whether the reflux component is active, which helps your GP evaluate what else might be in play.
Every Peptest result is accompanied by a report letter written specifically for the patient's GP, summarising the test methodology, the result, and the clinical implications. You do not need a GP referral to order Peptest — but the letter is designed to make your GP appointment more productive once you have your result.
Alginate Barrier Therapy
Gaviscon Advance is the only UK-licensed therapeutic specifically indicated for the treatment of LPR. This is a meaningful clinical distinction: it is not a general antacid being used off-label, but a formulation developed and licensed on the basis of evidence in laryngopharyngeal reflux specifically.
The mechanism of alginates is fundamentally different from PPIs. Rather than suppressing acid production, alginates form a physical raft on the surface of stomach contents after ingestion. This raft sits at the gastro-oesophageal junction, acting as a physical barrier that prevents reflux from travelling upward. For LPR specifically, the key property is that this raft can entrap pepsin and bile acids — not just neutralise acid — before they have the opportunity to reach the oesophagus and throat. This is why alginates are mechanistically better suited to LPR than acid-suppressing therapy: they address the route of reflux, not just its pH. The evidence base for this is the Strugala & Dettmar 2010 study on alginate therapy in extra-oesophageal reflux, which supports the use of alginates specifically for LPR presentations.
Dosing: The standard clinical regimen for Gaviscon Advance in LPR is 10ml three times daily after meals plus at bedtime (tds + nocte). The timing matters: taking Gaviscon Advance after eating allows it to form its raft on top of the meal, which is when the surface of stomach contents is most accessible. The bedtime dose addresses nocturnal reflux, which is particularly relevant for LPR because lying flat removes gravity as a barrier to upward reflux.
💊 Gaviscon Advance
- High-strength sodium or potassium alginate formulation
- Forms a thick, stable raft — physically blocks reflux at the gastro-oesophageal junction
- Licensed specifically for LPR in the UK
- Entraps pepsin and bile acids — not just acid neutralisation
- Dose: 10ml after meals + at bedtime (tds + nocte)
⚠️ Regular Gaviscon
- Lower alginate concentration — weaker raft formation
- Primarily antacid action — less effective physical barrier
- Licensed for heartburn and indigestion, not specifically LPR
- Not equivalent to Gaviscon Advance for LPR purposes
The clinical evidence for alginates in LPR has a direct link to the same scientific heritage behind Peptest. Professor Peter Dettmar — founder of RD Biomed and the researcher who established pepsin as the primary agent of laryngeal damage — spent the earlier part of his career as Global R&D Director of Gastrointestinals at Reckitt Benckiser Healthcare, where he was directly involved in developing both Gaviscon and Gaviscon Advance. With over 530 peer-reviewed papers to his name, he remained one of the world's leading publishers on alginate therapy in reflux disease throughout his career. His understanding of why alginates are particularly effective for LPR — not merely because they neutralise acid, but because they form a physical raft that entraps pepsin and bile acids before they can reach the oesophagus and throat — was shaped by the same pepsin research that underpins Peptest itself. The recommendation to use Gaviscon Advance in LPR is not generic advice: it comes from decades of work by the same researcher who understood the condition most deeply.
Dietary Modification in LPR
Dietary modification in LPR is not primarily about avoiding foods that feel uncomfortable or that trigger heartburn. It is about preventing the reactivation of pepsin that has already been deposited in laryngeal tissue. This distinction matters because it changes which foods are most relevant and why. Research by Johnston & Dettmar (2007) established that pepsin, once deposited in laryngeal cells, can be reactivated by an acid environment — meaning that an acidic food or drink can trigger a new cycle of cellular damage without any new reflux event occurring. The acid doesn't have to come from the stomach; it just has to reach the throat. For the full mechanism, see pepsin dietary reactivation on our science page.
☕ Coffee & Acidic Drinks
Coffee — including decaffeinated — is directly acidic and a potent pepsin reactivator. Citrus juices, fizzy drinks, and alcohol share this property. These are the most important dietary modifications for the majority of LPR patients.
🍊 Citrus & Tomato Products
Both are acidic enough to reactivate deposited pepsin. Tomato-based sauces, juices, and fresh citrus are worth reducing, particularly in the evenings when lying flat removes gravity's protective effect.
🍔 High-Fat Foods
Fatty meals slow gastric emptying and increase intra-abdominal pressure, both of which increase the likelihood of reflux events. The effect is on reflux frequency rather than pepsin reactivation directly.
🍷 Alcohol
Alcohol both lowers lower oesophageal sphincter pressure (increasing reflux frequency) and is directly acidic. Its effects are dose-dependent — complete elimination is not always necessary for milder presentations.
Lifestyle & Positional Measures
Elevate the Head of the Bed
Raising the head of the bed by 15–20cm (using bed risers or a wedge pillow under the mattress, not just the pillow) uses gravity to reduce nocturnal reflux. This is particularly important for LPR because nighttime reflux during sleep — when swallowing and protective reflexes are reduced — contributes significantly to ongoing laryngeal exposure.
Three-Hour Rule Before Lying Down
Avoid eating within three hours of lying down or going to bed. Gastric emptying typically takes 2–4 hours, and a full stomach presents a much larger surface of stomach contents that can reflux. Evening meals eaten late are a consistent aggravating factor in LPR presentations. Moving the last meal earlier, and avoiding post-dinner snacking, is often one of the most effective single lifestyle changes.
Weight Management
Excess abdominal weight increases intra-abdominal pressure and predisposes to reflux by pushing stomach contents upward against the lower oesophageal sphincter. Weight reduction in overweight patients reliably reduces reflux frequency. Even modest reductions — 5–10% of body weight — can produce measurable improvements in reflux symptoms.
Smoking Cessation
Smoking directly impairs lower oesophageal sphincter function and reduces saliva production — a natural buffering mechanism for the throat. It also impairs mucociliary clearance in the upper airways. For patients with LPR who smoke, cessation is a high-priority intervention: its effects on upper airway health go beyond reflux specifically.
Clothing & Posture
Tight clothing around the abdomen and waist increases intra-abdominal pressure in the same way as excess weight. This is particularly relevant post-meal. Slouched posture after eating similarly increases abdominal compression — brief upright activity (a short walk, for instance) after meals is preferable to sitting or lying in a reclined position.
Portion Size & Meal Timing
Large meals create greater intra-gastric pressure and slow emptying — both reflux-promoting. Smaller, more frequent meals reduce the volume of stomach contents at any given time. Late-night eating is one of the most consistent modifiable risk factors in LPR; many patients find that changing meal timing alone produces noticeable improvement within weeks.
Voice & Throat Care in LPR
For patients whose LPR primarily affects the voice — hoarseness, voice fatigue, reduced range, morning voice changes — targeted throat and vocal care is an important component of management alongside the systemic interventions described above. These measures reduce direct laryngeal trauma and support mucosal recovery. For a full description of the LPR symptoms affecting the voice and throat, including the mechanisms behind each, see our LPR symptoms guide.
The Next Frontier in LPR Treatment
Current LPR management is grounded in the pepsin mechanism — barrier therapy, dietary modification, and accurate diagnosis. The next frontier is direct pepsin inhibition. Dr Nikki Johnston and N-Zyme Biomedical are currently in Phase II clinical trials with fosamprenavir, the world's first pepsin-inhibiting drug. When it reaches patients, it will be the first treatment to target the molecular mechanism of LPR damage directly. In the meantime, Peptest provides the only available method to confirm whether pepsin is active — which is precisely the diagnostic foundation that any future pepsin-targeted therapy will require.
Monitoring Treatment with Peptest
One of the most challenging aspects of LPR management is knowing whether treatment is actually working. Symptoms can fluctuate for reasons unrelated to reflux — voice overuse, viral infections, allergies, dry air — and improvement (or lack of it) tells you something about your symptoms, not necessarily about your underlying pepsin activity.
Retesting with Peptest at 8–12 weeks after starting treatment provides an objective answer. If pepsin is no longer detected at the same threshold, that is direct evidence that the barrier therapy and dietary modifications are preventing pepsin from reaching the throat. If pepsin remains present at the same or higher levels, treatment is not achieving its intended effect — which is useful information: it may point to incomplete adherence, a need to adjust the alginate regimen, or the presence of contributing factors that require further investigation.
This is the only available method of monitoring LPR treatment response using a biomarker rather than symptom reporting alone. No other non-invasive test provides this information. pH monitoring and impedance testing measure events; Peptest measures the molecule responsible for damage — and can confirm whether that molecule is still present regardless of symptom status.
For patients who haven't yet confirmed their diagnosis and want to establish whether LPR is present before beginning treatment, see our LPR diagnosis guide.
- Baseline test — before or at the start of treatment
- Retest at 8–12 weeks on alginate + dietary modification
- Same three-sample collection protocol as initial test
- Positive result at retest → reflux still active, review treatment
- Negative result at retest → objective evidence of response
- Consider retesting if symptoms return after a period of remission
Confirm Your Reflux. Track Your Progress.
A three-sample home saliva test — processed in the UK, results in 48 hours, with a GP letter included.
Frequently Asked Questions About LPR Treatment
Know Whether Pepsin Is Still Active — Don't Guess
Symptom improvement tells you about your symptoms. A Peptest result tells you about your pepsin. For patients managing LPR, the difference matters — whether you're confirming diagnosis, establishing a treatment baseline, or monitoring whether your current approach is actually working.
Order Peptest Now £79.95 · Free UK Delivery · No GP Referral NeededCE-IVD Certified · ISO 13485:2016 · UK Laboratory, Hull · +44 (0) 1482 935020